- Merck will seek U.S. approval for pill as soon as possible
- If approved, would be 1st oral antiviral COVID-19 drug
- Merck shares rally, some vaccine makers fall
- U.S. government to buy 1.7 mln courses at $700 each
Oct 1 (Reuters) – An experimental antiviral pill developed by Merck & Co (MRK.N) could halve the chances of dying or being hospitalized for those most at risk of contracting severe COVID-19, according to data that experts hailed as a potential breakthrough in how the virus is treated.
If it gets authorization, molnupiravir, which is designed to introduce errors into the genetic code of the virus, would be the first oral antiviral medication for COVID-19.
Merck and partner Ridgeback Biotherapeutics said they plan to seek U.S. emergency use authorization for the pill as soon as possible and to make regulatory applications worldwide.
“An oral antiviral that can impact hospitalization risk to such a degree would be game-changing,” said Amesh Adalja, senior scholar at the Johns Hopkins Center for Health Security.
Current treatment options include Gilead Sciences Inc’s (GILD.O) infused antiviral remdesivir and generic steroid dexamethasone, both of which are generally only given once a patient has already been hospitalized.
“This is going to change the dialogue around how to manage COVID-19,” Merck Chief Executive Robert Davis told Reuters.
Existing treatments are “cumbersome and logistically challenging to administer. A simple oral pill would be the opposite of that,” Adalja added.
The results from the Phase III trial, which sent Merck shares up more than 9%, were so strong that the study is being stopped early at the recommendation of outside monitors.
Shares of Atea Pharmaceuticals Inc (AVIR.O), which is developing a similar COVID-19 treatment, were up more than 21% on the news.
Jefferies analyst Michael Yee said investors believe “people will be less afraid of COVID and less inclined to get vaccines if there is a simple pill that can treat COVID.”
Pfizer and Swiss drugmaker Roche Holding AG (ROG.S) are also racing to develop an easy-to-administer antiviral pill for COVID-19. For now, only antibody cocktails that have to be given intravenously are approved for non-hospitalized patients.
Scientists from the Terasaki Institute for Biomedical Innovation (TIBI) have developed a contact lens that can capture and detect exosomes, nanometer-sized vesicles found in bodily secretions which have the potential for being diagnostic cancer [...]
Among the total number of deaths caused by different types of cancer, esophageal cancer is the sixth most significant. Several conventional treatments, such as radiotherapy, chemotherapy, and surgery have multiple side effects, including off-target [...]
Cell membrane-coated nanoparticles, applied in targeted drug delivery strategies, combine the intrinsic advantages of synthetic nanoparticles and cell membranes. Although stem cell-based delivery systems were highlighted for their targeting capability in tumor therapy, inappropriate [...]
When babies in the African countries of Guinea Bissau and Uganda were given the tuberculosis vaccine, something remarkable happened. Instead of the vaccine only protecting against the target bacteria – Myocbacterium tuberculosis – the tuberculosis vaccine offered broad protection against a [...]
Thousands of years ago, across the Eastern Mediterranean, multiple Bronze Age civilizations took a distinct turn for the worse at around the same time. The Old Kingdom of Egypt and the Akkadian Empire both collapsed, and there was [...]
IN OCTOBER 2014, virologist Edward Holmes took a tour of the Huanan Seafood Wholesale Market in Wuhan, a once relatively overlooked city of about 11 million people in the central Chinese province of Hubei. The market would [...]
Self-healable ionic sensing materials with fatigue resistance are imperative in robotics and soft electronics for extended service life. The existing artificial ionic skins with self-healing capacity were prepared by network reconfiguration, constituting low-energy amorphous [...]
As demand for solar energy rises around the world, scientists are working to improve the performance of solar devices—important if the technology is to compete with traditional fuels. But researchers face theoretical limits on [...]
When shrimp shell nanoparticles were mixed into cement paste, the material became substantially stronger — researchers propose an innovation that could lead to less seafood waste and fewer carbon dioxide emissions from concrete production. [...]
A black-and-white video shared on social media showed a microscopic corkscrew-shaped helix as it appeared to consume a sperm, transport it, and ultimately lead the little swimmer into the wall of an [...]
Polymers containing quantum dots (QDs) are considered crucial components of next-generation consumer items, but ambiguity remains regarding how these compounds may negatively affect public health and the environment. A pre-proof paper from the Journal of Hazardous [...]
A new copper coating that kills bacteria quicker and in greater amounts than current formulations could soon be available for hospitals and other high-traffic facilities. Although current formulations made of pure copper are antibacterial [...]
A vaccination as tumor therapy - with a vaccine individually created from a patient's tissue sample that " attaches" the body's own immune system to cancer cells: the basis for this long-term vision has [...]
Although retinoic acid (RA) can induce cell death, its weak anticancer efficacy limits its clinical applications. To this end, stimulus-responsive self-assembling prodrug-based nanomedicines are promising candidates that enable controlled drug delivery. In an article [...]
Graphene is a multifunctional carbon nanomaterial widely synthesized for its applications in composites, energy storage, and sensors. Although previous reviews mentioned that achieving an increased yield compromises graphene quality, limiting its commercialization, recent research [...]
A new COVID variant has recently been detected in several countries including the UK, US, India, Australia and Germany. Called BA.2.75, it’s a subvariant of omicron. You might have also heard it called “Centaurus”, the [...]